Baqsimi is owned by Eli Lilly And Co.
Baqsimi contains Glucagon.
Baqsimi has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Baqsimi are:
Baqsimi was authorised for market use on 24 July, 2019.
Baqsimi is available in powder;nasal dosage forms.
Baqsimi can be used as treatment of severe hypoglycemia in patients with diabetes.
The generics of Baqsimi are possible to be released after 23 September, 2039.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6938798 | ELI LILLY AND CO | Fluid or powdery product dispensing device |
Jan, 2022
(1 year, 4 months ago) | |
US10213487 | ELI LILLY AND CO | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(12 years from now) | |
US10894133 | ELI LILLY AND CO | Device for dispensing a fluid product |
Jan, 2038
(14 years from now) | |
US10765602 | ELI LILLY AND CO | Medication delivery systems and methods |
Sep, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jul 24, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 24 July, 2019
Treatment: Treatment of severe hypoglycemia in patients with diabetes
Dosage: POWDER;NASAL
8
United States
7
European Union
6
Japan
4
China
4
France
3
Morocco
3
Australia
2
Canada
2
South Africa
1
Spain
1
Dominican Republic
1
Philippines
1
Malaysia
1
Moldova, Republic of
1
Denmark
1
RS
1
Poland
1
Germany
1
Brazil
1
Ukraine
1
Singapore
1
EA
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Guatemala
1
Cyprus
1
Peru
1
Chile
1
Israel
1
Portugal
1
El Salvador
1
Mexico
1
Costa Rica
1
Ecuador
1
Colombia
1
Lithuania
1
Saudi Arabia
1
Tunisia
1
Slovenia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic